共 50 条
Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma
被引:17
|作者:
Liu, Ken
[1
,2
,3
,7
]
Dennis, Claude
[1
]
Prince, David S.
[4
]
Marsh-Wakefield, Felix
[3
,5
]
Santhakumar, Cositha
[1
,3
,5
]
Gamble, Jennifer R.
[6
]
Strasser, Simone I.
[1
,2
]
McCaughan, Geoffrey W.
[1
,2
,3
]
机构:
[1] Royal Prince Alfred Hosp, Australian Natl Liver Transplant Unit, Sydney, NSW, Australia
[2] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[3] Centenary Inst, Liver Injury & Canc Program, Sydney, NSW, Australia
[4] Liverpool Hosp, Dept Gastroenterol, Sydney, NSW, Australia
[5] Univ Sydney, Human Immunol Lab, Sydney, NSW, Australia
[6] Centenary Inst, Ctr Endothelium, Vasc Biol Program, Sydney, NSW, Australia
[7] Royal Prince Alfred Hosp, AW Morrow Gastroenterol & Liver Ctr, Level 9,Missenden Rd, Camperdown, NSW 2050, Australia
来源:
关键词:
Vessels that encapsulate tumour clusters (VETC);
angiogenesis;
biomarker;
metastasis;
liver transplantation;
epithelial mesenchymal transition (EMT);
EPITHELIAL-MESENCHYMAL TRANSITION;
ANTIANGIOGENIC THERAPY;
MICROVESSEL DENSITY;
METASTASIS;
SORAFENIB;
ANGIOGENESIS;
BEVACIZUMAB;
PREDICTOR;
INVASION;
PLUS;
D O I:
10.1016/j.jhepr.2023.100792
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Vessels that encapsulate tumour clusters (VETC) is a distinct histologic vascular pattern associated with a novel mechanism of metastasis. First described in human cancers in 2004, its prevalence and prognostic significance in hepatocellular carcinoma (HCC) has only been appreciated in the past decade with a rapidly increasing body of literature. A robust biomarker of aggressive disease, the VETC pattern is easy to recognise but relies on histologic examination of tumour tissue for its diagnosis. Radiological recognition of the VETC pattern is an area of active research and is becoming increasingly accurate. As a prognostic marker, VETC has consistently proven to be an independent predictor of disease recurrence and overall survival in patients with HCC undergoing resection and liver transplantation. It can also guide treatment by predicting response to other therapies such as transarterial chemoembolisation and sorafenib. Without prospective randomised-controlled trials or routine evaluation of VETC in clinical practice, there are currently no firm treatment recommendations for VETC-positive tumours, although some perspectives are provided in this review based on the latest knowledge of their pathogenesis - a complex interplay between tumour angiogenesis and the immune microenvironment. Nevertheless, VETC has great potential as a future biomarker that could take us one step closer to precision medicine for HCC. & COPY; 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页数:13
相关论文